Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
CD20 antigens
immunotherapy
pemphigoid
pemphigus
rituximab
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
13
02
2018
accepted:
10
11
2018
pubmed:
27
12
2018
medline:
29
5
2019
entrez:
27
12
2018
Statut:
ppublish
Résumé
This was a multicenter study of rituximab, a chimeric monoclonal immunoglobulin G antibody directed against CD20, for the treatment of refractory autoimmune bullous diseases (pemphigus and pemphigoid). Ten patients (three with pemphigus vulgaris, six with pemphigus foliaceus and one with bullous pemphigoid) were treated with a single cycle of rituximab (four weekly infusions at a dose of 375 mg/m
Identifiants
pubmed: 30585649
doi: 10.1111/1346-8138.14732
doi:
Substances chimiques
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
124-130Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology of Japan
Organisme : Intramural research fund of Keio University School of Medicine
Organisme : Ministry of Health, Labor and Welfare of Japan
ID : H23-028
Informations de copyright
© 2018 Japanese Dermatological Association.